Process Chemists Have One of the Most Important Jobs in America

Process chemists have one of the most important jobs in America. They are the reason a drug that works in a flask becomes a drug that exists in a pharmacy, in quantity, at a price people can pay.

Almost nobody outside chemistry knows the job exists.

America is now spending hundreds of billions of dollars to bring drug manufacturing home, and the conversation is about buildings, tariffs, and pledges. Almost none of it is about the people who decide how a drug actually gets made. There are not enough of them here, and that is the part money does not fix quickly.

What a process chemist actually does

A discovery chemist's job ends when the molecule exists. They need a few hundred milligrams to run an assay, so the route can be ugly. It can use a reagent that costs four thousand dollars a gram. It can end in a column purification that eats a day. It can run at minus 78 degrees with a palladium catalyst loaded at 10 mol%. None of that matters at that scale.

A process chemist's job starts exactly there, and everything that was fine a moment ago is now a problem.

They have to turn that route into something that runs in a 4,000 liter reactor. It has to hit purity spec, produce a controlled and well understood impurity profile, avoid generating a mutagenic byproduct that regulators will ask about, use solvents the plant is permitted to handle, finish inside a shift, and land at a cost per kilogram that survives generic pricing.

That is usually a different route. Often a different disconnection strategy entirely.

Chromatography gets replaced with a crystallization, because you cannot run a column at ton scale. The cryogenic step gets replaced with a different base, because chilling a 4,000 liter vessel to minus 78 is not a thing you do. The palladium load drops from 10 mol% to 0.2 mol%, because at that scale the metal is both a cost line and a regulatory limit in the final product.

Every one of those calls is a judgment made with information that is not written down anywhere. Which reactions behave differently when the heat transfer changes. Which impurities purge in the crystallization and which ride all the way through. Which supplier's starting material carries iron that poisons the catalyst three steps later.

This is where the knowledge lives

When a country offshores manufacturing, people picture the plant leaving. The plant is the cheap part. What actually leaves is the judgment.

Manufacturing know-how in chemistry is not stored in documents. A tech transfer package tells you what was done, not why the fourth attempt failed or what the operator noticed about the slurry. That knowledge lives in chemists who have run campaigns, watched batches fail, and fixed them. It accumulates in the people, and it accumulates only by doing the work.

So when the work goes elsewhere for twenty years, the judgment goes with it, and it does not come back the moment you build a new plant.

The numbers

As of August 2019, the FDA counted 28% of the API manufacturing facilities supplying the US market as being located in the US. The EU accounted for 26%, India 18%, and China 13%. Put plainly, roughly seven in ten of the sites making the active ingredients in American medicine sat outside America.

The shift happened fast. Research cited by the Richmond Fed found that in the early 2000s only about 15% of factories supplying the US market were overseas, and by 2020 that figure had grown by more than 80%.

Volume tells a harsher story than facility counts. By 2024, about 12% of the API volume consumed in the US was produced domestically. India produces around 60% of global pill volume. The US produces 22%.

The consequences are measurable. Drugs produced in Asia are 54% more likely to go into shortage than drugs produced in the US, and those shortages run an average of 130 days longer. The FDA found that 60% of US supply interruption cases traced back to quality control problems.

Concentration is its own risk. About 90% of the domestically produced sterile saline used in the US comes from a single plant in western North Carolina.

Money is not the constraint

The policy response has been large. Fourteen manufacturers have now pledged over $480 billion in US production over the next four to ten years, covering 22 new manufacturing sites and roughly 44,000 jobs. Section 232 tariffs phase in through 2026 to force the issue, with default rates of 100% on patented drugs and reduced rates for companies with approved onshoring plans.

Two things stand in the way of that money turning into supply.

The first is economics. Generics account for roughly 90% of US prescriptions but only 13.1% of total drug spending. As John Murphy III of the Association for Accessible Medicines put it, if you already run facilities in Canada and India, justifying a billion dollar US facility to your board is a hard conversation. The drugs most exposed to shortage are the ones with the least margin to fund reshoring.

The second is people. CSIS research cited in coverage of the 2026 reshoring push names workforce shortfalls as a structural barrier to domestic manufacturing. You can finance a building in a quarter. You cannot finance twenty years of process chemistry experience.

The lever that moves quickly

If you cannot add chemists fast, the only remaining variable is how much each chemist gets through.

That is worth sitting with, because it is the opposite of how offshore manufacturing competes. Low cost economies compete on hours: more people, cheaper hours, more parallel attempts. You do not beat that by copying it. Nobody is putting forty chemists on one molecule in New Jersey.

You beat it by changing what a single expert covers.

Look at where a process chemist's week actually goes. Scouting routes. Reading through literature and patents to see whether a step has precedent. Hunting for a condition set that someone already got to work. Checking whether a reagent is even purchasable at scale and what the lead time looks like. Pulling batch data out of an ELN into a shape you can look at. Assembling a report a client will accept.

A large share of that is retrieval and formatting, not chemistry. It is the part that scales with headcount, which is exactly the part where a forty person team wins.

Two things have changed recently enough that most labs have not adjusted.

Route work got faster. Software can now generate a wide set of synthetic strategies for a target, apply a chemist's own constraints, and surface precedent with references attached. The chemist is still the one deciding. What changes is that they spend their time judging options instead of finding them. This is the problem we work on at Ryniant, and our current testing puts it at about 15% less chemist time per molecule from route planning to bench.

Building software got cheap. A chemist who can describe what they want can now build a working tool for their own data in an afternoon with something like Cursor. Not a platform. A script that parses last quarter's batch records and plots impurity level against jacket temperature. Two years ago that was a budget request, a vendor conversation, and a two quarter wait. Now it is a subscription and a Saturday.

Neither of these makes a chemist redundant. Both of them take the low judgment hours out of the week and hand them back.

The asymmetry

Cheap labor scales linearly. Forty chemists do roughly forty chemists of work.

Tooling scales differently. It raises the ceiling on how much ground one experienced decision maker can cover, and experienced decision makers are precisely what the US still has and cannot quickly make more of.

That is the asymmetry worth pressing. Not more hours. More molecules per chemist, with the judgment part left intact.

The reshoring conversation should widen past concrete and tariffs. The plants are being built. The question that decides whether they produce anything is whether the people running the chemistry inside them are equipped to work at a rate that headcount alone cannot match.